A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients

NCT02963389 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: Tripegfilgrastim

Sponsor

Dong-A ST Co., Ltd.